SinoMab BioScience
Manufacturing · China · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Science Park West Ave, Central and Weste...Website
www.sinomab.comRevenue
$13.9 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About SinoMab BioScience
SinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pemphigus vulgaris (PV), non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs.Explore more
SinoMab BioScience Org Chart
Get the full picture
Sign in to uncover key details.
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SinoMab BioScience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on SinoMab BioScience recently announced quarterly report
Product Launch: Get notified when SinoMab BioScience launches new products
Check out if SinoMab BioScience is spiking on competitors!
Check if SinoMab BioScience has recently received funding, and reach out quickly before it becomes old news!
SinoMab BioScience, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if SinoMab BioScience had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at SinoMab BioScience
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once SinoMab BioScience has new funding data
Recommended Actions
Find VP level buyers at SinoMab BioScience
Find 3 more new buyers
Company Profile Activity
Activity Insights
SinoMab BioScience is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SinoMab BioScience is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SinoMab BioScience.
SinoMab BioScience Tech Stack
A closer look at the technologies used by SinoMab BioScience
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
New Hire
Executive Move
SinoMab BioScience News & Media
SinoMab (03681.HK) Achieves Approximately 43.3% Year-over-Year Decrease in Annual Losses for 2025, Marking Significant Progress in Pipeline Advancement
HONG KONG, Mar 24, 2026 - (ACN Newswire) - SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”; stock code: 03681.HK) is pleased to announce its annual results for the year ended 31 December 2025 (the “Year”). During the year, loss for the year was approximately RMB105.0 million, decreased by RMB80.1 million from RMB185.1 million for the year ended 31 December 2024. The Company focused on SM17 Phase 1b clinical, transformationSinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis
HONG KONG, Apr 9, 2025 - (ACN Newswire) - SinoMab BioScience Limited (Stock Code: 3681.HK, “SinoMab” or the “Company”), is pleased to announce our breakthrough topline results from the completed Phase 1b clinical study evaluating SM17, a novel investigational therapy targeting the IL-25 (IL-17E) receptor pathway in moderate to severe atopic dermatitis (AD). SM17 uniquely binds to the co-receptor for IL-25, a key alarmin, and blocks downstream signaling – disrupting the inflammatory cascade driveSinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy
HONG KONG, Apr 16, 2024 - (ACN Newswire) - SinoMab BioScience Limited (Stock Code: 3681.HK, “SinoMab” or the “Company”), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases, is pleased to announce that the preclinical works of SM17, a humanised IgG4 monoclonal antibody against IL-17RB, is published on Allergy, an official journal of the European Academy of Allergy and CSinoMab's IND Application of SM17 has once again Received Approval from NAMP
HONG KONG, Sep 12, 2023 - (ACN Newswire) - A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company"), is pleased to announce that the Investigational New Drug application ("IND"), for the treatment of patients with atopic dermatitis ("AD") for the Company's First-in-Class (FIC) therapeutic product S
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SinoMab BioScience
Sign Up For FreeTo access detailed company insights
SinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and is currently in Pha... Read More
